Browsing by Author "Cinar, M."

Now showing 1 - 4 of 4

Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life treasure prospective data
(Clinical & Exper Rheumatology, 2021-07-01) Kimyon, G.; Kalyoncu, U.; Kiraz, S.; Bes, C.; Coskun, N.; Yagiz, B.; Kucuksahin, O.; Kanitez, N.; Erden, A.; Kilic, L.; Bilging, E.; Kasifoglu, T.; Emmungil, H.; Koca, S. S.; Akar, S.; Cinar, M.; Yazisiz, V; Ates, A.; Ersozlu, D.; Gonulle, E.; Mercan, R.; Ertenli, I; Coskun, N.; COŞKUN, NEJDET; Bursa Uludağ Üniversitesi/Tıp Fakültesi.
ObjectiveTo determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA).MethodsThe TReasure database is a web-based, prospective, observational cohort of RA and spondyloarthritis patients from 17 centres in different regions of Turkey and data entry was enabled since December 2017. Until May 2019,2556 RA patients on biologic treatment were recorded. Demographic and RA-related data of 1526 patient either received LEF or MTX were compared, efficacy of both drugs compared by RA-disease activity composite indices. Reasons fordrug discontinuation also recorded. Drug retention rates were compared with Kaplan-Meier curves (log-rank test).ResultsOf 2556 RA patients 1526 (59.7%) were receiving concomitant LEE (n=646, 42 3%; median follow up 35 months) or concomitant MTX (n=880, 573%; median follow-up 32 months) at the time of initiation to their first bDMARDs. The LEE group were older and had longer disease duration, proportion of females and seropositive patients was higher in this group. In the LEE group, non-anti-TNF agents were used in higher rate. Remission rates, changes in composite indices and rate of comorbidities and adverse events were similar in both groups. The retention rate of LEE + non-anti-TNF b/tsDMARDs was higher compared to MTX + anti-TNF bDMARDs (p=0.002, log-rank). Rates of adverse events were similar in both groups.ConclusionLEE in combination with either anti TNF or non anti DIF drugs appears as an effective and safe therapeutic option at least as MIX.
Biosimilar infliximab experience in spondyloartritis patients: Treasure real life results
(Bmj Publishing Group, 2020-06-01) Bilge, N. S. Yasar; Kasifoglu, T.; Kiraz, S.; Ertenli, A. I.; Bes, C.; Emmungil, H.; Cinar, M.; Akar, S.; Gercik, O.; Ersozlu, D.; Kimyon, G.; Mercan, R.; Kilic, L.; Kalyoncu, U.; Dalkilic, E.; DALKILIÇ, HÜSEYİN EDİZ; Seniz, B. N.; Yagiz, B.; YAĞIZ, BURCU; Karadag, O.; Pehlivan, Y.; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0002-3443-3117; AAV-7175-2021; JQW-5031-2023; AAD-5448-2019; AAG-8227-2021
Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: Cross-sectional data from the psoriatic arthritis-international database
(Clinical & Exper Rheumatology, 2021-05-01) Bilgin, E.; Aydin, S. Z.; Tinazzi, I.; Bayindir, O.; Kimyon, G.; Ozisler, C.; Dogru, A.; ; Aksu, K.; Cetin, G. Yildirim; Yilmaz, S.; Solmaz, D.; Omma, A.; Can, M.; Kucuksahin, O.; Yavuz, S.; Ersozlu, E. D.; Kilic, L.; Tarhan, E. F.; Tufan, M. Aydin; Akyol, L.; Cinar, M.; Erden, A.; Gonullu, E.; Yildiz, F.; Bakirci, S.; Erbasan, F.; Esmen, S. Ergulu; Kucuk, A.; Tufan, A.; Balkarli, A.; Mercan, R.; Erten, S.; Akar, S.; Kasifoglu, T.; Duruoz, T.; Yazisiz, V.; Kalyoncu, U.; Dalkılıç, E.; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.
ObjectiveTo explore the impact of early versus late-onset psoriasis (PsO) on the disease characteristics of psoriatic arthritis (PsA) in a large-multicentre cohort.MethodsThe data from a multicentre psoriatic arthritis database was analysed. Patients were grouped according to age at psoriasis onset (early onset; 40 years of age, late-onset; 40 years of age) and disease characteristics of the groups were compared by adjusting for BMI and PsA duration, where necessary.ResultsAt the time of analyses, 1634 patients were recruited [62.8% females; early onset 1108 (67.8%); late-onset, 526 (32.2%)]. The late-onset group was more over-weight [66.8% vs. 86.8%, p<0.001; adjusted for age -aOR 1.55 (1.11-2.20; 95% CI)]. The early onset group had more scalp psoriasis at onset (56.7% vs. 43.0%, p<0.001), whereas extremity lesions were more common in the late-onset group (63.8% vs. 74.2%, p<0.001). Axial disease in males and psoriatic disease family history in females were significantly higher in the early onset group [38.0% vs. 25.4%; p=0.005; adjusted for PsA duration -aOR 1.76 (1.19-2.62; 95% CI) / 39.5% vs. 30.1%; p=0.003; OR 1.51 (1.15-1.99; 95% CI), respectively]. Psoriatic disease activity parameters, patient-physician reported outcomes and HAQ-DI scores were similar in both groups.ConclusionClinical features of PsA may be affected by the age at onset of PsO. Different genetic backgrounds in early and late-onset PsO may be driving the differences in psoriasis and PsA phenotypes.
Do peripheral and extra musculoskeletal manifestations have an impact on biologic dmard prescribing patterns in axial spondyloarthritis: The results of treasure experience
(Bmj Publishing Group, 2021-06-01) Ediboglu, E. Durak; Solmaz, D.; Karadag, O.; Cinar, M.; Ertenli, A. I.; Ersozlu, D.; Kucuksahin, O.; Ates, A.; Kiraz, S.; Tekgoz, E.; Emmungil, H.; Gonullu, E.; Kabadayi, G.; Kasifoglu, T.; Mercan, R.; Kimyon, G.; Colak, S.; Bes, C.; Bilge, N. S. Yasar; Yazisiz, V.; Koca, S. S.; Atagunduz, P.; Kanitez, N. A.; Kalyoncu, U.; Akar, S.; Pehlivan, Y.; Coskun, B. N.; COŞKUN, NEJDET; Yagiz, B.; YAĞIZ, BURCU; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Kimya Bölümü.; 0000-0002-9035-689X; 0000-0003-1372-1555; 0000-0002-0866-1503; 0000-0001-5184-4404; 0000-0002-6990-4206; 0000-0003-2076-3403; 0000-0003-1185-5816; 0000-0002-3734-1242; HJY-2666-2023; JQW-5031-2023; HJI-6996-2023; AAG-7155-2021; GZA-3287-2022; B-1448-2016; AFO-6929-2022; AAZ-5845-2021; AAD-5448-2019; AAK-7851-2021; W-7332-2019